Advertisement
Advertisement

PGEN

PGEN logo

Precigen, Inc. Common Stock

4.49
USD
Sponsored
-0.04
-0.95%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

4.50

+0.01
+0.18%

PGEN Earnings Reports

Positive Surprise Ratio

PGEN beat 11 of 40 last estimates.

28%

Next Report

Date of Next Report
Mar 17, 2026
Estimate for Q4 25 (Revenue/ EPS)
$8.45M
/
-$0.08
Implied change from Q3 25 (Revenue/ EPS)
+189.23%
/
-92.45%
Implied change from Q4 24 (Revenue/ EPS)
+610.20%
/
+33.33%

Precigen, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, PGEN reported earnings of -1.06 USD per share (EPS) for Q3 25, missing the estimate of -0.09 USD, resulting in a -993.91% surprise. Revenue reached 2.92 million, compared to an expected 510.00 thousand, with a 472.94% difference. The market reacted with a +25.65% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.08 USD, with revenue projected to reach 8.45 million USD, implying an decrease of -92.45% EPS, and increase of 189.23% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Precigen, Inc. Common Stock reported EPS of -$1.06, missing estimates by -993.91%, and revenue of $2.92M, 472.94% above expectations.
The stock price moved up 25.65%, changed from $3.86 before the earnings release to $4.85 the day after.
The next earning report is scheduled for Mar 17, 2026.
Based on 5 analysts, Precigen, Inc. Common Stock is expected to report EPS of -$0.08 and revenue of $8.45M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement